366 related articles for article (PubMed ID: 27637852)
41. Management of multidrug-resistant tuberculosis: Update 2007.
Yew WW; Leung CC
Respirology; 2008 Jan; 13(1):21-46. PubMed ID: 18197909
[TBL] [Abstract][Full Text] [Related]
42. Extensively drug-resistant tuberculosis: current challenges and threats.
Jain A; Mondal R
FEMS Immunol Med Microbiol; 2008 Jul; 53(2):145-50. PubMed ID: 18479439
[TBL] [Abstract][Full Text] [Related]
43. Extensively drug-resistant tuberculosis in the United States, 1993-2007.
Shah NS; Pratt R; Armstrong L; Robison V; Castro KG; Cegielski JP
JAMA; 2008 Nov; 300(18):2153-60. PubMed ID: 19001626
[TBL] [Abstract][Full Text] [Related]
44. Extensively drug-resistant tuberculosis in India: Current evidence on diagnosis & management.
Prasad R; Singh A; Balasubramanian V; Gupta N
Indian J Med Res; 2017 Mar; 145(3):271-293. PubMed ID: 28749390
[TBL] [Abstract][Full Text] [Related]
45. Multidisciplinary advisory teams to manage multidrug-resistant tuberculosis: the example of the French Consilium.
Guglielmetti L; Jaffré J; Bernard C; Brossier F; El Helali N; Chadelat K; Thouvenin G; Dautzenberg B; Henry B; Jaspard M; Guillot H; Pourcher V; Le Dû D; Marigot-Outtandy D; Mougari F; Raskine L; Rivoire B; Andrejak C; Jarlier V; Aubry A; Robert J; Frechet-Jachym M; Veziris N
Int J Tuberc Lung Dis; 2019 Oct; 23(10):1050-1054. PubMed ID: 31627768
[No Abstract] [Full Text] [Related]
46. Prevalence of resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients in Viet Nam, 2011.
Nguyen HB; Nguyen NV; Tran HT; Nguyen HV; Bui QT
Western Pac Surveill Response J; 2016; 7(2):35-40. PubMed ID: 27508089
[TBL] [Abstract][Full Text] [Related]
47. New treatment options for multidrug-resistant tuberculosis.
Field SK; Fisher D; Jarand JM; Cowie RL
Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676
[TBL] [Abstract][Full Text] [Related]
48. Drug susceptibility patterns of Mycobacterium tuberculosis and clinical outcomes of drug-resistant tuberculosis at Srinagarind Hospital, a tertiary care center in northeastern Thailand.
Reechaipichitkul W; Tubtim S; Chaimanee P
Southeast Asian J Trop Med Public Health; 2011 Sep; 42(5):1154-62. PubMed ID: 22299441
[TBL] [Abstract][Full Text] [Related]
49. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
[TBL] [Abstract][Full Text] [Related]
50. Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis.
Ahmad S; Mokaddas E
J Infect Public Health; 2014; 7(2):75-91. PubMed ID: 24216518
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of the nitrate reductase assay for rapid detection of extensively drug-resistant tuberculosis.
Rosales S; Pineda-García L; Andino N; Almendarez N; Membreño H; Hoffner SE
Int J Tuberc Lung Dis; 2009 Dec; 13(12):1542-9. PubMed ID: 19919774
[TBL] [Abstract][Full Text] [Related]
52. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis.
Kim DH; Kim HJ; Park SK; Kong SJ; Kim YS; Kim TH; Kim EK; Lee KM; Lee SS; Park JS; Koh WJ; Lee CH; Shim TS
Am J Respir Crit Care Med; 2010 Jul; 182(1):113-9. PubMed ID: 20224066
[TBL] [Abstract][Full Text] [Related]
53. Rapid detection of drug resistance and mutational patterns of extensively drug-resistant strains by a novel GenoType® MTBDRsl assay.
Singh AK; Maurya AK; Kant S; Umrao J; Kushwaha RA; Nag VL; Dhole TN
J Postgrad Med; 2013; 59(3):179-85. PubMed ID: 24029194
[TBL] [Abstract][Full Text] [Related]
54. [Epidemiology of drug-resistant tuberculosis: world--Europe--Poland].
Jagielski T; Augustynowicz-Kopeć E; Zwolska Z
Wiad Lek; 2010; 63(4):345-57. PubMed ID: 21612049
[TBL] [Abstract][Full Text] [Related]
55. Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.
D'Ambrosio L; Centis R; Tiberi S; Tadolini M; Dalcolmo M; Rendon A; Esposito S; Migliori GB
J Thorac Dis; 2017 Jul; 9(7):2093-2101. PubMed ID: 28840010
[TBL] [Abstract][Full Text] [Related]
56. Extensively drug-resistant tuberculosis in california, 1993-2006.
Banerjee R; Allen J; Westenhouse J; Oh P; Elms W; Desmond E; Nitta A; Royce S; Flood J
Clin Infect Dis; 2008 Aug; 47(4):450-7. PubMed ID: 18616396
[TBL] [Abstract][Full Text] [Related]
57. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.
Bonnet M; Bastard M; du Cros P; Khamraev A; Kimenye K; Khurkhumal S; Hayrapetyan A; Themba D; Telnov A; Sanchez-Padilla E; Hewison C; Varaine F
Int J Tuberc Lung Dis; 2016 Feb; 20(2):177-86. PubMed ID: 26792469
[TBL] [Abstract][Full Text] [Related]
58. Survival of patients with multidrug-resistant TB in Eastern Europe: what makes a difference?
Balabanova Y; Ignatyeva O; Fiebig L; Riekstina V; Danilovits M; Jaama K; Davidaviciene E; Radiulyte B; Popa CM; Nikolayevskyy V; Drobniewski F
Thorax; 2016 Sep; 71(9):854-61. PubMed ID: 27012887
[TBL] [Abstract][Full Text] [Related]
59. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis.
Gandhi NR; Nunn P; Dheda K; Schaaf HS; Zignol M; van Soolingen D; Jensen P; Bayona J
Lancet; 2010 May; 375(9728):1830-43. PubMed ID: 20488523
[TBL] [Abstract][Full Text] [Related]
60. Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis.
Kunkel A; Cobelens FG; Cohen T
PLoS Med; 2016 Oct; 13(10):e1002142. PubMed ID: 27727274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
